<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39344698</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">3022-7712</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Clinical transplantation and research</Title><ISOAbbreviation>Clin Transplant Res</ISOAbbreviation></Journal><ArticleTitle>Remdesivir in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>212</StartPage><EndPage>221</EndPage><MedlinePgn>212-221</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4285/ctr.24.0031</ELocationID><Abstract><AbstractText Label="BACKGROUND">The use of remdesivir in solid organ transplant recipients (SOTRs) with coronavirus disease 2019 (COVID-19) has been studied. The present systematic review and analysis aimed to assess its effectiveness in this population.</AbstractText><AbstractText Label="METHODS">A comprehensive search of PubMed, Cochrane Library, Web of Science, Embase, medRxiv, and Google Scholar was conducted to identify relevant articles published up to April 2024. The quality of the included studies was evaluated using the Cochrane assessment tool. Data analysis was performed using the Comprehensive Meta-Analysis software ver. 3.0.</AbstractText><AbstractText Label="RESULTS">The meta-analysis included seven eligible retrospective studies, involving a total of 574 SOTRs. The findings indicated no significant differences in mortality rate (odds ratio [OR], 1.19; 95% confidence interval [CI], 0.59-2.39), hospitalization rate (OR, 0.69; 95% CI, 0.10-4.79), need for mechanical ventilation (OR, 0.98; 95% CI, 0.44-2.18), or need for oxygen therapy (OR, 3.73; 95% CI, 0.75-18.34) between the groups that received remdesivir and those that did not. However, a statistically significant difference was observed in the rate of intensive care unit admissions between the two groups (OR, 2.39; 95% CI, 1.24-4.57).</AbstractText><AbstractText Label="CONCLUSIONS">Our meta-analysis found that remdesivir offers no clinical benefits to SOTRs infected with COVID-19. Additional high-quality research is required to assess the potential clinical advantages of remdesivir for SOTRs with COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Navidi</LastName><ForeName>Zia</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-6716-8228</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pakzad Moghadam</LastName><ForeName>Seyed Hamid</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-5456-0017</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iravani</LastName><ForeName>Mojgan Mohajeri</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0001-8279-6273</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Faculty of Paramedical Sciences, AJA University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orandi</LastName><ForeName>Amirhossein</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6822-7568</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orandi</LastName><ForeName>Amirali</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0000-4887-2869</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, Sina Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghazi</LastName><ForeName>Samrand Fattah</ForeName><Initials>SF</Initials><Identifier Source="ORCID">0000-0001-6590-3436</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallah</LastName><ForeName>Ehsan</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1781-2665</Identifier><AffiliationInfo><Affiliation>Department of Orthopedics, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malekabad</LastName><ForeName>Ebadallah Shiri</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0002-4466-2511</Identifier><AffiliationInfo><Affiliation>School of Nursing, AJA University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khorramnia</LastName><ForeName>Saeed</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7305-9298</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Clin Transplant Res</MedlineTA><NlmUniqueID>9918787371206676</NlmUniqueID><ISSNLinking>3022-6783</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Organ transplantation</Keyword><Keyword MajorTopicYN="N">Remdesivir</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>
<b>Conflict of Interest</b>
. No potential conflict of interest relevant to this article was reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39344698</ArticleId><ArticleId IdType="pmc">PMC11464156</ArticleId><ArticleId IdType="doi">10.4285/ctr.24.0031</ArticleId><ArticleId IdType="pii">ctr.24.0031</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Danziger-Isakov L, Blumberg EA, Manuel O, Sester M. Impact of COVID-19 in solid organ transplant recipients. Am J Transplant. 2021;21:925–37. doi: 10.1111/ajt.16449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16449</ArticleId><ArticleId IdType="pmc">PMC9800718</ArticleId><ArticleId IdType="pubmed">33319449</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke JA, Wiemken TL, Korenblat KM. Excess mortality among solid organ transplant recipients in the United States during the COVID-19 pandemic. Transplantation. 2022;106:2399–407. doi: 10.1097/TP.0000000000004341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004341</ArticleId><ArticleId IdType="pmc">PMC9696767</ArticleId><ArticleId IdType="pubmed">36042551</ArticleId></ArticleIdList></Reference><Reference><Citation>Søfteland JM, Li H, Magnusson JM, Leach S, Friman V, Gisslén M, et al. COVID-19 outcomes and vaccinations in Swedish solid organ transplant recipients 2020-2021: a nationwide multi-register comparative cohort study. Viruses. 2024;16:271. doi: 10.3390/v16020271.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16020271</ArticleId><ArticleId IdType="pmc">PMC10893154</ArticleId><ArticleId IdType="pubmed">38400046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu TH, Kim HY, Ahn J, Oh JS, Kim JK. Delayed exacerbation of COVID-19 pneumonia in vaccinated kidney transplant recipients receiving immunosuppressants: a case series. Korean J Transplant. 2023;37:63–8. doi: 10.4285/kjt.22.0043.</Citation><ArticleIdList><ArticleId IdType="doi">10.4285/kjt.22.0043</ArticleId><ArticleId IdType="pmc">PMC10090830</ArticleId><ArticleId IdType="pubmed">37064773</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahalingasivam V, Craik A, Tomlinson LA, Ge L, Hou L, Wang Q, et al. A systematic review of COVID-19 and kidney transplantation. Kidney Int Rep. 2021;6:24–45. doi: 10.1016/j.ekir.2020.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2020.10.023</ArticleId><ArticleId IdType="pmc">PMC7607258</ArticleId><ArticleId IdType="pubmed">33163708</ArticleId></ArticleIdList></Reference><Reference><Citation>Jering KS, McGrath MM, Mc Causland FR, Claggett B, Cunningham JW, Solomon SD. Excess mortality in solid organ transplant recipients hospitalized with COVID-19: a large-scale comparison of SOT recipients hospitalized with or without COVID-19. Clin Transplant. 2022;36:e14492. doi: 10.1111/ctr.14492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ctr.14492</ArticleId><ArticleId IdType="pmc">PMC8646895</ArticleId><ArticleId IdType="pubmed">34558116</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanego F, Vigara LA, Alonso M, Orellana C, Gómez AM, Eady M, et al. Trends in COVID-19 outcomes in kidney transplant recipients during the period of omicron variant predominance. Transplantation. 2022;106:e304–5. doi: 10.1097/TP.0000000000004126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004126</ArticleId><ArticleId IdType="pmc">PMC9128401</ArticleId><ArticleId IdType="pubmed">35389374</ArticleId></ArticleIdList></Reference><Reference><Citation>Amani B, Zareei S, Amani B, Zareei M, Zareei N, Shabestan R, et al. Artesunate, imatinib, and infliximab in COVID-19: a rapid review and meta-analysis of current evidence. Immun Inflamm Dis. 2022;10:e628. doi: 10.1002/iid3.628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.628</ArticleId><ArticleId IdType="pmc">PMC9092000</ArticleId><ArticleId IdType="pubmed">35634954</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Luo D, Mei B, Du J, Liu X, Xie H, et al. Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: a systematic review and meta-analysis. Clin Microbiol Infect. 2023;29:441–56. doi: 10.1016/j.cmi.2022.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.12.004</ArticleId><ArticleId IdType="pmc">PMC9733302</ArticleId><ArticleId IdType="pubmed">36509376</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh K, Kang M, Kim YE, Choi Y, An SJ, Seong J, et al. Risk of severe COVID-19 and protective effectiveness of vaccination among solid organ transplant recipients. J Infect Dis. 2024;229:1026–34. doi: 10.1093/infdis/jiad501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad501</ArticleId><ArticleId IdType="pubmed">38097377</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Liu M, Li Z, Xu J, Zhang J, Tian J. Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials. Clin Microbiol Infect. 2023;29:979–99. doi: 10.1016/j.cmi.2023.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.04.014</ArticleId><ArticleId IdType="pmc">PMC10116122</ArticleId><ArticleId IdType="pubmed">37084941</ArticleId></ArticleIdList></Reference><Reference><Citation>Amani B, Amani B. Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2024:1–9. doi: 10.1080/14787210.2024.2326561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2024.2326561</ArticleId><ArticleId IdType="pubmed">38457124</ArticleId></ArticleIdList></Reference><Reference><Citation>Amani B, Akbarzadeh A, Amani B, Shabestan R, Khorramnia S, Navidi Z, et al. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: a systematic review and meta-analysis. J Med Virol. 2023;95:e28889. doi: 10.1002/jmv.28889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28889</ArticleId><ArticleId IdType="pubmed">37368841</ArticleId></ArticleIdList></Reference><Reference><Citation>Angamo MT, Mohammed MA, Peterson GM. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. Infection. 2022;50:27–41. doi: 10.1007/s15010-021-01671-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01671-0</ArticleId><ArticleId IdType="pmc">PMC8325414</ArticleId><ArticleId IdType="pubmed">34331674</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585:273–6. doi: 10.1038/s41586-020-2423-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2423-5</ArticleId><ArticleId IdType="pmc">PMC7486271</ArticleId><ArticleId IdType="pubmed">32516797</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacho J, Nicolás D, Bodro M, Cuadrado-Payán E, Torres-Jaramillo V, Gonzalez-Rojas Á, et al. Use of remdesivir in kidney transplant recipients with SARS-CoV-2 Omicron infection. Kidney Int. 2022;102:917–21. doi: 10.1016/j.kint.2022.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2022.08.001</ArticleId><ArticleId IdType="pmc">PMC9367173</ArticleId><ArticleId IdType="pubmed">35964801</ArticleId></ArticleIdList></Reference><Reference><Citation>Fesu D, Bohacs A, Hidvegi E, Matics Z, Polivka L, Horvath P, et al. Remdesivir in solid organ recipients for COVID-19 pneumonia. Transplant Proc. 2022;54:2567–9. doi: 10.1016/j.transproceed.2022.10.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2022.10.043</ArticleId><ArticleId IdType="pmc">PMC9626440</ArticleId><ArticleId IdType="pubmed">36400587</ArticleId></ArticleIdList></Reference><Reference><Citation>Solera JT, Árbol BG, Bahinskaya I, Marks N, Humar A, Kumar D. Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave. Am J Transplant. 2023;23:78–83. doi: 10.1111/ajt.17199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.17199</ArticleId><ArticleId IdType="pmc">PMC9538117</ArticleId><ArticleId IdType="pubmed">36148607</ArticleId></ArticleIdList></Reference><Reference><Citation>Villamarín M, Márquez-Algaba E, Esperalba J, Perelló M, Los Arcos I, Company D, et al. Preliminary clinical experience of molnupiravir to prevent progression of COVID-19 in kidney transplant recipients. Transplantation. 2022;106:2200–4. doi: 10.1097/TP.0000000000004306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004306</ArticleId><ArticleId IdType="pubmed">35915545</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG PRISMA Group, author. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9. doi: 10.7326/0003-4819-151-4-200908180-00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-151-4-200908180-00135</ArticleId><ArticleId IdType="pubmed">19622511</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Coello PA, Guyatt GH, Yepes-Nuñez JJ, Akl EA, Hazlewood G, et al. GRADE guidelines: 20. assessing the certainty of evidence in the importance of outcomes or values and preferences-inconsistency, imprecision, and other domains. J Clin Epidemiol. 2019;111:83–93. doi: 10.1016/j.jclinepi.2018.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2018.05.011</ArticleId><ArticleId IdType="pubmed">29800687</ArticleId></ArticleIdList></Reference><Reference><Citation>Colaneri M, Amarasinghe N, Rezzonico L, Pieri TC, Segalini E, Sambo M, et al. Early remdesivir to prevent severe COVID-19 in recipients of solid organ transplant: a real-life study from Northern Italy. Int J Infect Dis. 2022;121:157–60. doi: 10.1016/j.ijid.2022.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.05.001</ArticleId><ArticleId IdType="pmc">PMC9076039</ArticleId><ArticleId IdType="pubmed">35533831</ArticleId></ArticleIdList></Reference><Reference><Citation>Elec F, Magnusson J, Elec A, Muntean A, Antal O, Moisoiu T, et al. COVID-19 and kidney transplantation: the impact of remdesivir on renal function and outcome - a retrospective cohort study. Int J Infect Dis. 2022;118:247–53. doi: 10.1016/j.ijid.2022.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.03.015</ArticleId><ArticleId IdType="pmc">PMC8920078</ArticleId><ArticleId IdType="pubmed">35301103</ArticleId></ArticleIdList></Reference><Reference><Citation>Razia D, Sindu D, Grief K, Cherrier L, Omar A, Walia R, et al. Molnupiravir vs remdesivir for treatment of Covid-19 in lung transplant recipients. J Heart Lung Transplant. 2023;42:S165–6. doi: 10.1016/j.healun.2023.02.1653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2023.02.1653</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorramnia S, Navidi Z, Orandi A, Iravani MM, Orandi A, Malekabad ES, et al. Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis. Clin Transplant Res. 2024;38:136–44. doi: 10.4285/ctr.24.0015.</Citation><ArticleIdList><ArticleId IdType="doi">10.4285/ctr.24.0015</ArticleId><ArticleId IdType="pmc">PMC11228381</ArticleId><ArticleId IdType="pubmed">38904088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CK, Lau KT, Au IC, Xiong X, Chung MS, Lau EH, et al. Optimal timing of remdesivir initiation in hospitalized patients with coronavirus disease 2019 (COVID-19) administered with dexamethasone. Clin Infect Dis. 2022;75:e499–508. doi: 10.1093/cid/ciab728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab728</ArticleId><ArticleId IdType="pmc">PMC8513400</ArticleId><ArticleId IdType="pubmed">34420051</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsawah HK, Elsokary MA, Abdallah MS, ElShafie AH. Efficacy and safety of remdesivir in hospitalized Covid-19 patients: systematic review and meta-analysis including network meta-analysis. Rev Med Virol. 2021;31:e2187. doi: 10.1002/rmv.2187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2187</ArticleId><ArticleId IdType="pubmed">33128490</ArticleId></ArticleIdList></Reference><Reference><Citation>Amani B, Shabestan R, Rajabkhah K, Amani B. Sotrovimab in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis. Korean J Transplant. 2023;37:277–85. doi: 10.4285/kjt.23.0038.</Citation><ArticleIdList><ArticleId IdType="doi">10.4285/kjt.23.0038</ArticleId><ArticleId IdType="pmc">PMC10772269</ArticleId><ArticleId IdType="pubmed">37916433</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhand A, Okumura K, Ohira S, Kapur R, Wolfe K, Nishida S. Molnupiravir for treatment of COVID-19 in solid organ transplant recipients. Transplantation. 2023;107:e182–3. doi: 10.1097/TP.0000000000004588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004588</ArticleId><ArticleId IdType="pmc">PMC10205063</ArticleId><ArticleId IdType="pubmed">36959161</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Li Y, Song T. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: a review of immunosuppressant adjustment strategies. Front Immunol. 2023;14:1150341. doi: 10.3389/fimmu.2023.1150341.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1150341</ArticleId><ArticleId IdType="pmc">PMC10111375</ArticleId><ArticleId IdType="pubmed">37081880</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386:305–15. doi: 10.1056/NEJMoa2116846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116846</ArticleId><ArticleId IdType="pmc">PMC8757570</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzitelli M, Trunfio M, Sasset L, Scaglione V, Ferrari A, Mengato D, et al. Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: a real-life cohort study. J Med Virol. 2023;95:e28660. doi: 10.1002/jmv.28660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28660</ArticleId><ArticleId IdType="pubmed">36905216</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso-Navarro R, Ramírez M, Masiá M, Paredes R, Montejano R, Povar-Echeverria M, et al. Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses. BMC Infect Dis. 2023;23:286. doi: 10.1186/s12879-023-08222-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08222-y</ArticleId><ArticleId IdType="pmc">PMC10157565</ArticleId><ArticleId IdType="pubmed">37142994</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy Vegivinti CT, Pederson JM, Saravu K, Gupta N, Barrett A, Davis AR, et al. Remdesivir therapy in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Ann Med Surg (Lond) 2021;62:43–8. doi: 10.1016/j.amsu.2020.12.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2020.12.051</ArticleId><ArticleId IdType="pmc">PMC7806502</ArticleId><ArticleId IdType="pubmed">33489115</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>